Author

M. Rupji

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Organism:Drosophila· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

B. Dwivedi· 2 shared C.-S. Seong· 2 shared M. Gilbert-Ross· 2 shared A. C. Boese· 1 shared A. I. Marcus· 1 shared A. J. Murphy· 1 shared A. L. Christie· 1 shared A. L. Hong· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

B. Dwivedi

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesis.

C.-S. Seong, C. Huang, A. C. Boese, Y. Hou, J. Koo, J. K. Mouw, M. Rupji, G. Joseph, H. R. Johnston, H. Claussen, J. M. Switchenko, M. Behera, M. Churchman, J. M. Kolesar, S. M. Arnold, , M. Gilbert-Ross

The paper shows that loss of HD-PTP, a tumor suppressor, promotes RAS-driven oncogenesis and is associated with adenosquamous lung cancer, suggesting it as a therapeutic target.

bioRxiv · Jan 26, 2023 · PreprintCancer Biology

Targeting TRIP13 in Wilms Tumor with Nuclear Export Inhibitors

K. Mittal, B. P. Lee, G. W. Cooper, J. Shim, H. C. Jonus, W. J. Kim, M. Doshi, D. Almanza, B. D. Kynnap, A. L. Christie, X. Yang, G. S. Cowley, B. A. Leeper, C. L. Morton, B. Dwivedi, , A. L. Hong

This study identifies XPO1 inhibition with selinexor as a potential therapy for favorable histology Wilms tumors, showing synergy with doxorubicin in preclinical models.

bioRxiv · Feb 23, 2022Cancer Biology

The level of oncogenic Ras controls the malignant transformation of Lkb1 mutant tissue in vivo.

B. Rackley, C.-S. Seong, E. Kiely, R. E. Parker, M. Rupji, B. Dwivedi, J. M. Heddleston, W. Giang, N. Anthony, T.-L. Chew, M. Gilbert-Ross

A Drosophila model shows that high oncogenic Ras levels drive malignant transformation in Lkb1 mutant tissue, with implications for human lung adenocarcinoma.

bioRxiv · Sep 25, 2020Cancer Biology